Core Insights - The company reported a revenue of RMB 7.519 billion for the six months ending June 30, 2025, representing a year-on-year increase of 4.8% [1] - The profit attributable to shareholders for the period was RMB 1.894 billion, which is a 27% increase compared to the previous year [1] - Basic earnings per share were RMB 1.0426, and the company proposed an interim dividend of RMB 0.16 per share [1] Segment Performance - Revenue from intermediates, active pharmaceutical ingredients (APIs), and formulation products were RMB 2.304 billion, RMB 2.999 billion, and RMB 3.9785 billion, respectively, showing a year-on-year decline of 25.2%, 23.4%, and an increase of 65.9% [1] - Segment profits for intermediates, APIs, and formulation products were RMB 634.6 million, RMB 250.6 million, and RMB 1.5056 billion, reflecting a year-on-year decline of 40.6%, 52.0%, and an increase of 524.2% [1]
联邦制药发布中期业绩，股东应占溢利18.94亿元 同比增加27%